Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (1993)	6/28/1998 4:13:00 PM
From: drdan	Read Replies (1) \| Respond to of 5402

probably not.As best as I know, approval is usually given for particular uses, and all "reasonable" doses for a given application are explored prior to approval.For transfusion use, I would guess that the FDA would want to see efficacy and safety in doses approximating the total blood volume of a human.That is what they did in some trials with other synthetic blood products . Does anyone else know otherwise, or would someone want to call the FDA to make sure that I am correct?